Introduction
============

Colorectal cancer (CRC) is the third leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-8042]). Recurrence and metastasis are the major causes of mortality in patients with CRC ([@b2-ol-0-0-8042],[@b3-ol-0-0-8042]). Although screening, surgical techniques and adjuvant chemotherapy for patients with CRC have been developed to achieve a significant improvement in survival time ([@b4-ol-0-0-8042],[@b5-ol-0-0-8042]), the 5-year overall survival (OS) rate of CRC remains at \~65% ([@b6-ol-0-0-8042]). The stage of CRC at the time of diagnosis is a key factor for deciding the therapeutic regimen and assessing prognosis. However, at the time of diagnosis, the majority of patients exhibit intermediate- or late-stage disease ([@b7-ol-0-0-8042],[@b8-ol-0-0-8042]). Therefore, efficient diagnostic and predictive biomarkers are required for early-stage diagnosis in order to improve the prognosis of patients with CRC.

The mitochondrial tumor necrosis factor receptor-associated protein-1 (TRAP-1) is one of the 90 isoforms of heat shock protein (HSP) and is also termed HSP75 ([@b9-ol-0-0-8042],[@b10-ol-0-0-8042]). TRAP-1 has been demonstrated to serve an effective function in stabilizing cellular homeostasis and regulating mitochondrial integrity ([@b11-ol-0-0-8042],[@b12-ol-0-0-8042]). By antagonizing cyclophilin D (CypD), TRAP-1 serves a cytoprotective function for cells responding to apoptotic stimuli and enables tumor cell survival in a hostile environment ([@b13-ol-0-0-8042]). It has been reported that TRAP-1 protects cancer cells from apoptosis by blocking mitochondrial effects ([@b14-ol-0-0-8042]). Additionally, increasing evidence has demonstrated that increased TRAP-1 expression is observed in cancerous tissues of the breast, lung, prostate and pancreas as compared with the corresponding normal tissues ([@b15-ol-0-0-8042]--[@b17-ol-0-0-8042]). A previous study also demonstrated that TRAP-1 expression level is associated with lymph node metastasis in CRC ([@b18-ol-0-0-8042]). These aforementioned results indicate that TRAP-1 is a potential candidate biomarker for breast, lung and prostate cancer, as well as CRC, and may be a cancer-specific therapeutic target. However, only a limited number of studies have evaluated the prognostic relevance of TRAP-1 expression based on clinical data of CRC.

The aim of the present study was to investigate the association between TRAP-1 expression and the clinicopathological features of patients with CRC, including tumor-node-metastasis (TNM) stage, degree of pathological differentiation, and lymph node metastasis, as well as to demonstrate any clinical significance of TRAP-1 expression in CRC prognosis.

Materials and methods
=====================

### Patients and follow-up

A total of 256 patients diagnosed with CRC, and who underwent surgical resection at PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology of Wuhan (Wuhan, China) between 1 January 2004 and 31 December 2009, were investigated in the present study. None of the patients received neoadjuvant chemotherapy or radiotherapy prior to surgery. Among the 256 patients, 226 patients received 5-fluorouracil (5-FU)-based chemotherapy following surgical resection, including 5-FU alone (5-FU/leucovorin; 500 mg/m^2^ 5-FU on days 1--5 and 200 mg/m^2^ leucovorin on days 1--5, capecitabine (a 5-FU derivative) alone (1,250 mg/m^2^, twice daily on days 1--14), and 5-FU combined with oxaliplatin (500 mg/m^2^ 5-FU on days 1--5, and 130 mg/m^2^ oxaliplatin on day 1). These 226 cases underwent a 21-day cycle chemotherapy for 8 cycles.

By December 31st, 2014, at the end of follow-up, the median follow-up time was 60 months (range, 1--60 months). The outpatient and inpatient medical records, physical exams, complete blood biochemical detection, serum carcinoembryonic antigen and carbohydrate antigen 19-9 measurements, ultrasound and endoscopic examinations, as well as computed tomography scans, were conducted to monitor the status of patients every 3--6 months. Differentiation grading and TNM classification for enrolled patients with colorectal cancer were based on the 7th American Joint Committee on Cancer TNM staging system ([@b19-ol-0-0-8042]).

The OS time was defined as the interval from the date of CRC surgery until mortality from any cause. Progression-free survival (PFS) was defined as the interval from a particular treatment to the first evidence of progression or recurrence, or to disease-associated mortality.

All procedures used in the present study involving human participants were approved by the Ethics Committee of PuAi Hospital of Tongji Medical College, Huazhong University of Science and Technology, and were performed in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

### Tissue specimens

Samples of 256 paired CRC tissues and paracancerous tissues were collected and examined. To assess metastatic CRC, 33 metastatic CRC tissue samples from 25 cases were selected for analysis (multiple-site metastases were present in 8 cases), including 4 cases metastasized to the pelvis, 4 cases metastasized to the liver, 2 cases metastasized to the lung, 2 cases metastasized to the bladder, 15 cases metastasized to the peritoneum and 6 cases metastasized to other organs, such as the ovaries. To assess lymph node metastasis, \>12 lymph nodes were obtained and studied. A total of 53 cases of patients who underwent colonoscopy were also examined, including 25 cases of colorectal adenoma and 28 cases of colorectal high-grade intraepithelial neoplasia. All specimens were fixed in 10% formalin for 24 h at room temperature and embedded in paraffin.

### Immunohistochemistry (IHC) for TRAP-1

Sections from formalin-fixed, paraffin embedded human colorectal tissues measuring 3-µm thick were sectioned on slides. The sections were then deparaffinized at room temperature with xylene, hygradated with ethyl alcohol in the descending gradients (100, 95 and 75%) and washed in distilled water several times. Antigen retrieval was conducted using Heat Induced Epitope Retrieval with a pressure-cooker for 10 min after the pressure starting beating in 0.01 M citrate antigen retrieval solution (pH 6.0). Subsequent to cooling to room temperature, those sections were processed with 0.3% H~2~O~2~ methanol for 10 min to remove endogenous peroxidase activity at room temperature. IHC staining for TRAP-1 was conducted as previously described ([@b20-ol-0-0-8042],[@b21-ol-0-0-8042]). Briefly, slides were incubated with a monoclonal rabbit anti-TRAP-1 primary antibody (clone EPR5381, cat. no. ab109323, dilution 1:200; Abcam, Cambridge, MA, USA;) at 4°C overnight, followed by incubation with a horseradish peroxidase-labeled goat anti-rabbit IgG secondary antibody (cat. no. A-11035; dilution 1:500; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA;) at 37°C for 2 h. Slides were scored by two experienced pathologists according to intensity and proportion of immunostaining using an upright optical microscope (Olympus Corporation, Tokyo, Japan). Immunostaining was assessed in 5 high-powered fields at magnification, ×200. Cytoplasmic staining of epithelial cells was considered positive. The intensity of immunohistochemical staining (0, negative; 1, weak; 2, intermediate; 3, strong) and the percentage of positive cells (0, \<5% positive cells; 1, 5--25% positive cells; 2, 26--50% positive cells; 3, \>50% positive cells) were evaluated. As for calculating the percentage of positive cells of each slide, 5 fields of high power lens were selected for observation. The final score for each section was assessed by multiplying the scores of staining intensity and percentage of positive cells. The immunohistochemical staining score was calculated by taking the average of the staining scores assigned by each pathologist, according to the formula \[(score 1: Percentage of area stained × staining intensity) + (score 2: Percentage of area stained × staining intensity)\]/2, as previously described ([@b18-ol-0-0-8042]). The two scores were evaluated by two pathologists respectively. For statistical analysis, tissue specimens were divided into the following four groups according to their immunohistochemical score: Negative (staining score, 0); positive (staining score, 1--12); low (staining score, 1--4); intermediate (staining score, 5--8); and high (staining score, 9--12).

### Statistical analysis

Statistical analyses were performed using SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA). For comparative analysis of qualitative variables, Pearson\'s χ^2^ test and Fisher\'s exact test were used to evaluate the association between the expression levels of TRAP-1 and clinical factors. OS and PFS were analyzed using Kaplan-Meier Plot, and the log-rank test was performed to detect the significance of prognostic factors. Cox\'s proportional hazards model was applied to identify independent predictive factors for survival. All P-values were two-sided, and P\<0.05 were considered to indicate a statistically significant difference.

Results
=======

### Clinical characteristics of patients with CRC

In the 256 cases of CRC analyzed, patient age at diagnosis ranged from 29--80 years (mean ± SD, 61.9±11.0 years). Among these cases, 122 patients (47.7%) were male and 134 (52.3%) patients were female. The primary tumor site was the colon in 151 (59.0%) patients and the rectum in 105 (41.0 %) patients. Lymph node metastases were present in 117 (45.7%) patients ([Table I](#tI-ol-0-0-8042){ref-type="table"}).

### Expression of TRAP-1 in CRC and its clinicopathological association

TRAP-1 expression was investigated in paired cancerous and paracancerous tissue sections in 256 patients with CRC. Positive expression was observed in 203/256 (79.3%) cancerous tissue samples and in 25/256 (9.8%) paracancerous tissue samples. In positive samples, TRAP-1 was primarily localized in the cytoplasm of colorectal epithelial cells. The positive expression levels were significantly increased in cancerous tissues compared with paracancerous tissue samples (P\<0.001; [Fig. 1A](#f1-ol-0-0-8042){ref-type="fig"}). A total of 77 (30.1%) samples of cancerous tissue displayed high TRAP-1 expression, 86 (33.6%) samples exhibited intermediate TRAP-1 expression, 40 (15.6%) samples exhibited low TRAP-1 expression, and 53 (20.7%) samples exhibited negative TRAP-1 expression.

In the present study, the associations between TRAP-1 expression and clinicopathological features were analyzed. For the purpose of this analysis, the high expression group comprised patients who possessed a TRAP-1 expression score of 9--12 (n=77, 30.1%), while all other patients (with intermediate, low or negative TRAP-1 expression) were assigned to the low expression group (n=179, 69.9%). Clinicopathological features included sex (male vs. female), age (\<65 vs. ≥65 years), primary tumor location (colon vs. rectum), TNM stage, \[stage I/II (defined as early stage) vs. stage III/IV (defined as advanced stage)\], tumor invasion (T1/T2 vs. T3/T4), histodifferentiation (well/moderate vs. poor) and lymph node metastasis (N0 vs. N1/N2). The results demonstrated that TRAP-1 expression levels were associated with the degree of differentiation (P=0.011), depth of invasion (T stage; P=0.006), lymph node metastasis (N stage; P\<0.001) and TNM stage (P\<0.001; [Table II](#tII-ol-0-0-8042){ref-type="table"}; [Fig. 1B](#f1-ol-0-0-8042){ref-type="fig"}). No significant association was observed between TRAP-1 expression and sex, age or tumor location (P\>0.05; [Table II](#tII-ol-0-0-8042){ref-type="table"}).

In addition, 25 colorectal adenoma tissues and 28 colorectal high-grade intraepithelial neoplasia tissues were analyzed. The results demonstrated weakly positive TRAP-1 expression (staining score, 1--3) in all 28 high-grade intraepithelial neoplasia tissues as well as in 2/25 colorectal adenoma tissues, whereas 23 of 25 colorectal adenoma tissues exhibited negative TRAP-1 expression ([Fig. 1A](#f1-ol-0-0-8042){ref-type="fig"}).

### Cancer recurrence/metastasis according to TRAP-1 expression status

During the follow-up period, cancer recurrences or metastases were detected in 144/256 (56.3%) patients and at 239 different sites, including anastomotic stoma/pelvic (63 cases), liver (47 cases), lung (34 cases), abdominal cavity/peritoneum (43 cases), regional lymph nodes (26 cases), bone/brain (13 cases) and other unusual sites (13 cases). In these cases, tissues of multiple metastatic sites were detected. The TRAP-1 expression levels in distant metastatic tissues of 22 patients were analyzed, including 11 cases of liver, 6 cases of lung and 5 cases of peritoneal metastasis. High TRAP-1 expression was determined in all metastatic peritoneal tissues. However, in contrast to peritoneal and lymph node metastases, low TRAP-1 expression was detected in all metastatic liver tissues with respect to normal liver tissues. This indicated an inverse association between TRAP-1 expression levels and liver metastasis. In addition, all metastatic lung tissues exhibited low TRAP-1 expression, in comparison with normal lung tissues, which exhibited negative TRAP-1 expression ([Fig. 1B](#f1-ol-0-0-8042){ref-type="fig"}).

### Survival analysis according to TRAP-1 expression or expression intensity

Among the 256 patients, 128 mortalities (50.0%) occurred within 5 years. Kaplan-Meier curves and log-rank tests were applied to determine the association between TRAP-1 expression and 5-year OS and PFS rates, respectively ([Fig. 2](#f2-ol-0-0-8042){ref-type="fig"}). As is demonstrated in [Fig. 2A and B](#f2-ol-0-0-8042){ref-type="fig"}, TRAP-1 positive expression was significantly associated with decreased 5-year OS (P=0.006) and PFS (P=0.001) rates in patients with CRC.

Patients with CRC were analyzed according to high and low TRAP-1 expression groups. Patients with high TRAP-1 expression experienced a 5-year OS rate of 38.0%, compared with 56.5% for patients with low TRAP-1 expression (P=0.003). Median OS times were 35.7 and 60.0 months for the high and low TRAP-1 expression groups, respectively. Similarly, the 5-year PFS rate was 26.6% for patients with high TRAP-1 expression and 53.3% for patients with low TRAP-1 expression (P\<0.001), and the median PFS times were 21.5 and 60.0 months for the high and low TRAP-1 expression groups, respectively. Patients with CRC with high TRAP-1 expression exhibited shorter OS and PFS times compared with patients with low TRAP-1 expression ([Fig. 2C and D](#f2-ol-0-0-8042){ref-type="fig"}).

### Prognostic factors associated with TRAP-1 expression status

Univariate analysis demonstrated a significant association between positive TRAP-1 expression and poor OS (P=0.008) and PFS (P=0.001) times. Multivariate analyses using Cox\'s regression model revealed positive TRAP-1 expression as an independent prognostic factor for both OS \[hazard ratio (HR), 1.914; 95% confidence interval (CI), 1.133--3.233; P=0.015\] and PFS (HR, 2.534; 95% CI, 1.534--4.212; P\<0.001) ([Table III](#tIII-ol-0-0-8042){ref-type="table"}).

Furthermore, multivariate analysis demonstrated that an advanced stage, poor Eastern Cooperative Oncology Group ([@b20-ol-0-0-8042]) performance status, poor tumor differentiation, and the absence of surgery or chemotherapy were independent prognostic factors for cancer-specific OS and PFS times. In addition, no significant association of other factors, such as sex and primary tumor site, with either cancer-specific OS or PFS were identified (P\>0.05; [Table III](#tIII-ol-0-0-8042){ref-type="table"}).

Discussion
==========

The present study evaluated the clinical and prognostic significance of TRAP-1 expression in 256 patients with CRC. The results demonstrated that the expression level of TRAP-1 was increased in cancerous tissues compared with adjacent noncancerous tissues, suggesting that TRAP-1 may exhibit a function in CRC tumorigenesis and progression. This result is consistent with reported studies from lung, breast, colorectal and pancreatic adenocarcinomas ([@b15-ol-0-0-8042]--[@b17-ol-0-0-8042]). In addition, in the present study, similar percentages of TRAP-1 overexpression were detected in primary colon and rectal cancer tissues (30.5 and 29.5%, respectively), indicating that TRAP-1 expression does not differ between colon and rectal cancers.

Clinicopathological parameters serve important functions for predicting prognosis and determining the most suitable CRC therapy ([@b22-ol-0-0-8042]--[@b24-ol-0-0-8042]). In the present study, a significant association was demonstrated between an increasing TRAP-1 expression and clinicopathological characteristics of CRC, including differentiation, depth of cancer invasion and presence of lymph node metastasis. Specifically, it was observed that TRAP-1 expression is a predictor for lymph node metastatic spread; this result was in accordance with a previous study of CRC ([@b18-ol-0-0-8042]) where TRAP-1 positive samples in patients with CRC were more frequently associated with lymphatic metastasis compared with TRAP-1 negative samples. Additionally, TRAP-1 expression was increased in metastatic lymph nodes compared with matched *in situ* tumor tissues in the present study. Therefore, the association between TRAP-1 expression and the aforementioned clinicopathological factors may implicate TRAP-1 as critical in CRC progression. In turn, TRAP-1 expression may serve as a molecular marker for lymph node metastasis and poor prognosis. However, no significant association was observed between TRAP-1 expression and the clinicopathological parameters of tumor differentiation and depth of cancer invasion in a previous study ([@b18-ol-0-0-8042]), and this is inconsistent with the results of the present study. In addition, in the present study no significant difference was indicated between the level of TRAP-1 expression in CRC tissues and other factors, including sex, age and tumor localization (P\>0.05).

However, in the present study, TRAP-1 expression levels from different distant metastatic tissues revealed some contradictory results. Metastatic cancerous tissue of the peritoneum demonstrated an overexpression of TRAP-1, whereas metastatic cancerous tissue of the lung exhibited low expression of TRAP-1. These results suggested that TRAP-1 expression differs between distinct metastatic CRC tissues, and the TRAP-1 expression level in metastatic lung cancer tissues is inconsistent with TRAP-1 expression levels in primary lung tumor tissues ([@b16-ol-0-0-8042]). Furthermore, TRAP-1 was expressed abundantly in normal liver tissues, whereas TRAP-1 expression was decreased in metastatic liver cancer tissues, indicating that TRAP-1 expression level is inversely associated with metastatic liver cancer.

Notably, TRAP-1 expression levels increased gradually from the colorectal mucosa of high-grade intraepithelial neoplasia to CRC. This suggests that TRAP-1 expression may be detected at the earliest stage of CRC tumorigenesis, and TRAP-1 may serve a function not only in the progression, but also in the onset of malignancy. This suggests that TRAP-1 may be gradually activated during colorectal carcinogenesis. To the best of our knowledge, there were several studies that noted TRAP-1 expression status in colorectal mucosa of high-grade intraepithelial neoplasia. Previous data obtained from CRC associated with ulcerative colitis demonstrated increased TRAP-1 expression and the degree of inflammation in CRC tissues only, but not in acute inflammation tissues ([@b25-ol-0-0-8042]). These results, in combination with those of the present study, suggest that TRAP-1 expression may occur in the earlier stages of tumorigenesis and that acute inflammation is not likely to influence TRAP-1 expression.

The progression of CRC primarily involves tumor differentiation, local infiltration, lymph node metastasis and distant metastasis. These stages are closely associated with cancer cell proliferation and invasion ([@b26-ol-0-0-8042]). A number of studies have identified that TRAP-1 expression is upregulated in metastatic cancer cells ([@b15-ol-0-0-8042],[@b22-ol-0-0-8042]) and is involved in oncogenesis by contributing to the inhibition of cancer cell apoptosis ([@b27-ol-0-0-8042],[@b28-ol-0-0-8042]). Other studies have identified that TRAP-1 is abundantly localized in the mitochondria of tumor cells ([@b13-ol-0-0-8042],[@b17-ol-0-0-8042]) and is involved in protecting against oxidative stress and apoptosis ([@b27-ol-0-0-8042],[@b29-ol-0-0-8042]--[@b31-ol-0-0-8042]). These results demonstrate the anti-apoptotic role of TRAP-1 in cancer cells. In addition, functional studies on the lung adenocarcinoma cell line A549 and the human breast cancer cell line MDA-MB-231 demonstrated that TRAP-1 expression is positively associated with cell proliferation *in vitro* ([@b28-ol-0-0-8042]). These significant functions of TRAP-1 in promoting cell proliferation and inhibiting apoptosis may explain the association between TRAP-1 expression levels and clinicopathological characteristics of CRC observed in the present study, including local infiltration, lymph node metastasis and distant metastasis.

A number of previous studies have demonstrated that the main roles of TRAP-1 are in tumor progression, protection from oxidative damage and cell survival ([@b9-ol-0-0-8042],[@b29-ol-0-0-8042]). TRAP-1 interacts with CypD, a mitochondrial permeability transition pore regulator, to suppress the main cell death pathway maintained by CypD ([@b10-ol-0-0-8042],[@b27-ol-0-0-8042]). Therefore, cytoprotection mediated by the upregulated expression of TRAP-1 may be an indicator for the onset of tumorigenesis. Furthermore, it has been reported that TRAP-1 functions synergistically with tumor necrosis factor receptor 1 to modulate the expression of the cell adhesion molecule N-cadherin, while altering the inter-cellular adhesion of neuronal cells through the signal transducer and activator of transcription 3 phosphorylation status ([@b17-ol-0-0-8042],[@b32-ol-0-0-8042]). This demonstrates the role of TRAP-1 in the processes of cell invasion and motility, which are characteristics of tumorigenesis and metastatic spread. In addition, previous studies have demonstrated that TRAP-1 regulates genes involved in the cell cycle and metastasis ([@b28-ol-0-0-8042]). The present study also indicated that cytoprotective mitochondrial chaperone TRAP-1 may be viewed as a molecular target in localized and metastatic CRC.

In the present study, follow-up analysis revealed that TRAP-1 expression was associated with cancer-specific 5-year OS and PFS rates in 256 patients with CRC, independent of the degree of TRAP-1 expression. Patients with positive or high TRAP-1 expression experienced poorer rates of cancer-specific 5-year OS and PFS compared with patients with negative or low TRAP-1 expression. Univariate and multivariate analyses revealed that TRAP-1 expression is an independent prognostic factor for cancer-specific OS and PFS of CRC. These observations support previous studies suggesting that overexpression of TRAP-1 is associated with a shortened OS time in other types of cancer, including breast, lung and prostate cancer ([@b15-ol-0-0-8042]--[@b17-ol-0-0-8042]).

A major limitation of the present study is the limited number of cases (n=256). A study on an increased scale is required to confirm the clinical significance of TRAP-1 expression. Due to the multiple roles of TRAP-1 in cellular functioning, future research is required to elucidate the mechanisms underlying TRAP-1 expression and its role in cancer cell biology.

In conclusion, the present study demonstrated the association between TRAP-1 expression and cancer-specific OS and PFS of human CRC. As well as this, overexpression of TRAP-1 was identified to be an adverse prognostic factor for patients with CRC. Further studies on an increased scale will be required to validate these results.
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![Representative IHC staining of TRAP-1 in colorectal tissues (magnification, ×200). (A) IHC staining in differently differentiated CRC tissues: (a) Adjacent non-tumor colorectal tissues with negative TRAP-1 expression; (b) TRAP-1 staining in an exemplary case of colorectal tubular adenoma tissues with negative TRAP-1 expression; (c) TRAP-1 staining in an exemplary case of colorectal high-grade intraepithelial neoplasia tissues with low TRAP-1 expression; (d) well-differentiated CRC tissues with low TRAP-1 expression; (e) moderately differentiated CRC tissues with intermediate TRAP-1 expression; and (f) poorly differentiated CRC tissues with high TRAP-1 expression. (B) IHC staining in CRC tissues at different T stages: (a) T2 stage CRC tissues with low TRAP-1 expression; (b) T3 stage CRC tissues with intermediate TRAP-1 expression; (c) T4 stage CRC tissues with high TRAP-1 expression; (d) TRAP-1 staining in lymph node metastatic CRC tissues with high TRAP-1 expression; (e) TRAP-1 staining in metastatic peritoneum tissues of CRC with high TRAP-1 expression; (f) TRAP-1 staining in metastatic lung tissues of CRC with low TRAP-1 expression and in normal lung tissues with negative TRAP-1 expression; (g) TRAP-1 staining in normal liver tissues with high TRAP-1 expression; (h) TRAP-1 staining in metastatic liver tissues of CRC with low TRAP-1 expression. Grading of differentiation status and TNM classification for CRC were based on the 7th American Joint Committee on Cancer TNM staging system ([@b19-ol-0-0-8042]). IHC, immunohistochemical; TRAP-1, tumor necrosis factor receptor-associated protein-1; CRC, colorectal cancer.](ol-15-04-5451-g00){#f1-ol-0-0-8042}

![Kaplan-Meier curves (log-rank test) for the correlation of OS and PFS with TRAP-1 expression. (A) OS and (B) PFS according to positive vs. negative TRAP-1 expression. (C) OS and (D) PFS according to high vs. low TRAP-1 expression. TRAP-1, tumor necrosis factor receptor-associated protein-1; OS, overall survival; PFS, progression-free survival.](ol-15-04-5451-g01){#f2-ol-0-0-8042}

###### 

Baseline characteristics of patients with colorectal cancer (n=256).

  Characteristics                                                n (%)
  -------------------------------------------------------------- ------------
  Age, years                                                     
    \<65                                                         140 (54.7)
    ≥65                                                          116 (45.3)
  Sex                                                            
    Male                                                         122 (47.7)
    Female                                                       134 (52.3)
  Site of primary tumor                                          
    Colon                                                        151 (59.0)
    Rectum                                                       105 (41.0)
  N staging                                                      
    N0                                                           139(54.3)
    N1-N2                                                        117(45.7)
  TNM stage^[a](#tfn1-ol-0-0-8042){ref-type="table-fn"}^         
    I                                                            25 (9.8)
    II                                                           113 (44.1)
    III                                                          93 (36.3)
    IV                                                           25 (9.8)
  Surgery                                                        
    Curative resection intent                                    230 (89.8)
    Palliative resection                                         26 (10.2)
  Chemotherapy                                                   
    Yes                                                          226 (88.3)
    No                                                           30 (11.7)
  Differentiation^[a](#tfn1-ol-0-0-8042){ref-type="table-fn"}^   
    Well-differentiated                                          58 (22.6)
    Moderately differentiated                                    129 (50.4)
    Poorly differentiated                                        69 (27.0)
  ECOG performance status                                        
    0                                                            159 (62.1)
    1                                                            73 (28.5)
    2                                                            24 (9.4)

Differentiation grading and TNM classification for colorectal cancer were based on the 7th American Joint Committee on Cancer TNM staging system (19). ECOG, Eastern Cooperative Oncology Group; TNM, tumor-node-metastasis.

###### 

Association between TRAP-1 expression and clinicopathological features.

                                                                                         Expression intensity of TRAP-1, n (%)               
  -------------------------------------------------------------------------------- ----- --------------------------------------- ----------- ---------
  All patients                                                                     256   179 (69.9)                              77 (30.1)   
  Sex                                                                                                                                        0.240
    Male                                                                           122   81 (66.4)                               41 (33.6)   
    Female                                                                         134   98 (73.1)                               36 (26.9)   
  Age, years                                                                                                                                 0.605
    \<65                                                                           140   96 (68.6)                               44 (31.4)   
    ≥65                                                                            116   83 (71.6)                               33 (28.4)   
  Tumor location                                                                                                                             0.872
    Rectum                                                                         105   74 (70.5)                               31 (29.5)   
    Colon                                                                          151   105 (69.5)                              46 (30.5)   
  Differentiation^[a](#tfn2-ol-0-0-8042){ref-type="table-fn"}^                                                                               0.011
    Well/moderately differentiated                                                 187   139 (74.3)                              48 (25.7)   
    Poorly differentiated                                                          69    40 (58.0)                               29 (42.0)   
  Depth of invasion (pT status)^[a](#tfn2-ol-0-0-8042){ref-type="table-fn"}^                                                                 0.006
    T1/T2                                                                          32    29 (90.6)                               3 (9.4)     
    T3/T4                                                                          224   150 (67.0)                              74 (33.0)   
  Lymph node metastasis (pN status)^[a](#tfn2-ol-0-0-8042){ref-type="table-fn"}^                                                             \<0.001
    N0                                                                             139   114 (82.0)                              25 (18.0)   
    N1/N2                                                                          117   65 (55.6)                               52 (44.4)   
  pTNM stage^[a](#tfn2-ol-0-0-8042){ref-type="table-fn"}^                                                                                    \<0.001
    I/II                                                                           138   107 (77.5)                              31 (22.5)   
    III/IV                                                                         118   65 (55.1)                               53 (44.9)   

Differentiation grading and TNM classification for colorectal cancer were based on the 7th American Joint Committee on Cancer TNM staging system ([@b19-ol-0-0-8042]). TRAP-1, tumor necrosis factor receptor-associated protein-1; pTNM, pathological tumor-node-metastasis.

###### 

Univariate and multivariate analyses for OS and PFS of patients with colorectal cancer (n=256).

                                                                                          Univariate analysis   Multivariate analysis                                      
  --------------------------------------------------------------------------------------- --------------------- ----------------------- --------- -------- --------------- ---------
  Sex (male vs. female)                                                                                                                                                    
    OS                                                                                    0.815                 0.576--1.153            0.248     ND       ND              ND
    PFS                                                                                   0.741                 0.534--1.028            0.073     ND       ND              ND
  Age (≥65 vs. \<65 years)                                                                                                                                                 
    OS                                                                                    1.619                 1.143--2.294            0.007     1.022    0.700--1.494    0.910
    PFS                                                                                   1.551                 1.118--2.152            0.009     1.182    0.837--1.668    0.342
  Location (rectum vs. colon)                                                                                                                                              
    OS                                                                                    0.936                 0.658--1.331            0.712     ND       ND              ND
    PFS                                                                                   0.932                 0.668--1.299            0.676     ND       ND              ND
  TNM stage (I/II vs. III/IV)^[a](#tfn3-ol-0-0-8042){ref-type="table-fn"}^                                                                                                 
    OS                                                                                    5.144                 3.491--7.581            \<0.001   11.325   2.580--49.713   0.001
    PFS                                                                                   4.215                 2.963--5.995            \<0.001   2.511    1.661--3.795    \<0.001
  Differentiation (well/moderate vs. poor)^[a](#tfn3-ol-0-0-8042){ref-type="table-fn"}^                                                                                    
    OS                                                                                    3.777                 2.656--5.372            \<0.001   2.641    1.773--3.933    \<0.001
    PFS                                                                                   3.335                 2.372--4.690            \<0.001   2.219    1.514--3.252    \<0.001
  ECOG performance status (0 vs. 1 vs. 2)                                                                                                                                  
    OS                                                                                    3.399                 2.655--4.352            \<0.001   1.591    1.169--2.165    0.003
    PFS                                                                                   2.922                 2.305--3.705            \<0.001   1.585    1.171--2.146    0.003
  Surgery (radical surgery vs. palliative surgery)                                                                                                                         
    OS                                                                                    0.135                 0.086--0.212            \<0.001   0.345    0.202--0.589    \<0.001
    PFS                                                                                   0.165                 0.105--0.261            \<0.001   0.386    0.226--0.658    \<0.001
  Chemotherapy (yes vs. no)                                                                                                                                                
    OS                                                                                    0.456                 0.283--0.735            0.001     0.323    0.192--0.542    \<0.001
    PFS                                                                                   0.592                 0.369--0.949            0.030     0.548    0.35--0.899     0.017
  TRAP-1 expression (negative vs. positive)                                                                                                                                
    OS                                                                                    1.997                 1.198--3.328            0.008     1.914    1.133--3.233    0.015
    PFS                                                                                   2.253                 1.374--3.695            0.001     2.534    1.534--4.212    \<0.001

Differentiation grading and TNM classification for colorectal cancer based on the 7th American Joint Committee on Cancer TNM staging system ([@b19-ol-0-0-8042]). OS, overall survival; PFS; progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; TNM, tumor-node-metastasis; ND, not determined; TRAP-1, tumor necrosis factor receptor-associated protein-1.

[^1]: Contributed equally
